Insmed Stock Plummets 19%. This Is What Sparked the Selloff.

Core Viewpoint - The biopharmaceutical company has decided to discontinue the development of a drug aimed at treating a chronic sinus condition [1] Group 1 - The company is halting the development of a specific drug [1]